PCA
BPMC

Providence Capital Advisors’s Blueprint Medicines BPMC Stock Holding History

Providence Capital Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17
Closed -$1K – 311
2022
Q1 		$1K Buy
+17
New +$1.22K ﹤0.01% 413

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Providence Capital Advisors's BPMC Position: Q2 2022 in Review

Providence Capital Advisors sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 17 shares — an estimated $1K sold.

Providence Capital Advisors first reported a position in BPMC in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

  • Providence Capital Advisors reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
  • Providence Capital Advisors sold 17 Blueprint Medicines shares in Q2 2022, an estimated $1K.
  • Providence Capital Advisors first reported a position in Blueprint Medicines in Q1 2022 and held it in 1 quarter.
  • Providence Capital Advisors's Blueprint Medicines position peaked at $1K in Q1 2022.
  • 237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on Providence Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.